Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents

• Published in: Revista española de enfermedades digestivas Vol. 111; no. 2; pp. 129 - 133
• Main Authors: Gutiérrez García, María Luisa, Manzano Alonso, María Luisa, Ferrer Rosique, Juan Ángel, Muñoz Gómez, Raquel, Alonso López, Sonia, Fernández Álvarez, Inmaculada, Fernández Rodríguez, Conrado M
• Format: Journal Article
• Language: English; Spanish
• Published: Spain Sociedad Espanola de Patologia Digestivas 01-02-2019
• Subjects: Adult; Aged; Aged, 80 and over; Antiviral Agents - therapeutic use; Biomarkers - blood; Coinfection - virology; Female; Hepatitis B Surface Antigens - analysis; Hepatitis B virus - immunology; Hepatitis B virus - isolation & purification; Hepatitis B virus - physiology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Hepatitis B, Chronic - virology; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Humans; Male; Middle Aged; Spain; Virus Activation; Young Adult; Spain
• ISSN: 1130-0108
• DOI: 10.17235/reed.2018.5667/2018

cases of hepatitis B virus (HBV) reactivation have been reported in patients with hepatitis C virus (HCV) treated with direct antiviral agents (DAA).
the main objectives of the present study are: a) to determine the prevalence of HBV/HCV coinfection in HCV patients treated with DAAs in the Autonomous Community of Madrid (CM) and also to determine the incidence and clinical relevance of HBV reactivation; and b) to determine the HBV screening rates in HCV patients in our region. For that purpose, 1,337 HCV patients were consecutively treated with DAAs in two hospitals located in South CM between January 2015 and June 2017.
nine of the 1,337 (0.67%) participants were HBsAg positive and 356 (26.6%) had previous HBV infection markers. Two of the four (50%) HBsAg positive patients with untreated HBV developed a virological reactivation, but not a biochemical reaction. Of the 356 patients with previous HBV infection markers, all had normal transaminases at the end of treatment and during follow-up. The HBV screening rate amounted to 92.9% of the cohort.
the prevalence of HBV (HBsAg positive) infection in patients with chronic hepatitis C in the southern area of the CM is low. HBV reactivation in HBsAg positive patients treated with DAAs is common, although without clinical relevance. In our region, there is a high rate of HBV screening in patients with HCV that are likely treated with DAAs.